Clinical trials: Epithelial Tumors, Malignant
Head and Neck Squamous Cell Carcinoma
Pembrolizumab in HNSCC With Residual Disease After Radiation
This is a phase II study for patients with squamous cell carcinoma of the head and neck who have residual disease following definitive therapy with radiation (with or without systemic therapy).
- Trial name
- NCT02892201
- Testing
- Pembrolizumab
- Where
- 2 sites in United States
- Volunteers
- 9 people
- Sponsor
- Yale University
Renal Cell Carcinoma
Low Dose Decitabine + Interferon Alfa-2b in Advanced Renal Cell Carcinoma
Primary Objective: To determine the progression-free survival (PFS) times for patients with advanced renal cell carcinoma (RCC) treated with decitabine and interferon alfa-2b.
- Trial name
- NCT00561912
- Testing
- Decitabine, Interferon Alfa-2b
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- M.D. Anderson Cancer Center
Lung Cancer, Non-Small Cell
A Phase II Trial of Lapatinib (TYKERB) + Pemetrexed (ALIMTA) in Advanced Non Small Cell Lung Cancer With an Initial Dose Finding Phase
This phase II study is a single-arm, two-stage, multicentre study to determine the clinical activity of lapatinib in combination with pemetrexed in patients with Non-Small Cell Lung Cancer (NSCLC) who have received one prior…
- Trial name
- NCT00528281
- Testing
- Lapatinib, Pemetrexed
- Where
- 5 sites in Germany, Italy and 2 more
- Volunteers
- 18 people
- Sponsor
- GlaxoSmithKline
Locally Advanced or Metastatic Solid Carcinomas, Colon Cancer
A Phase 1 Study Evaluating the Safety of TRK-950 in Patients With Advanced Solid Tumors
1. To determine the maximum tolerated dose (MTD) and the dose limiting toxicities (DLTs) of TRK-950 as single agent 2. To establish the dose of TRK-950 recommended for future phase 2 studies
- Conditions
- Locally Advanced or Metastatic Solid Carcinomas, Colon Cancer, Cholangiocarcinoma
- Trial name
- NCT02990481
- Testing
- TRK-950
- Where
- 3 sites in United States, France
- Volunteers
- 38 people
- Sponsor
- Toray Industries, Inc
Breast Cancer, Hot Flashes
Acupuncture in Treating Hot Flashes in Women With Breast Cancer
RATIONALE: Acupuncture may help relieve hot flashes in women with breast cancer. It is not yet known whether acupuncture is more effective than a placebo in treating hot flashes in women with breast cancer PURPOSE: This…
- Trial name
- NCT00081965
- Testing
- acupuncture therapy, hot flashes attenuation, management of therapy complications
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Hepatocellular Carcinoma
Randomized Phase II Trial of Chemoembolization and Sorafenib
The study will be a single-center, randomized Phase II study of conventional TACE in combination with sorafenib, given either continuously or sequentially, in patients with unresectable HCC.
- Trial name
- NCT02908165
- Testing
- conventional TACE in combination with sorafenib, administered on a continuous schedule, conventional TACE in combination with sorafenib, administered on a sequential schedule
- Where
- United States
- Sponsor
- Yale University
Medullary Thyroid Cancer, Medullary Carcinoma
Is Desmoplastic Stromal Reaction Useful to Modulate Lymph Node Dissection in Sporadic Medullary Thyroid Carcinoma?
The oncologic benefit of lateral neck dissection (LND) during index operation for sporadic medullary thyroid carcinoma (MTC) basing on basal calcitonin (bCT) levels has been questioned due to the potential post-operative…
- Conditions
- Medullary Thyroid Cancer, Medullary Carcinoma, Medullary Tumor, Medullary Neoplasms
- Trial name
- DSR-MTC (NCT06243965)
- Where
- Italy
- Volunteers
- 246 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Urothelial Carcinoma
Immunotherapy in Upper Tract Urothelial Carcinoma
Upper-tract urothelial carcinoma (UTUC) is a rare tumor. Standard treatment of localized disease is most often radical nephroureterectomy.
- Trial name
- VESUVIO (NCT06113367)
- Testing
- Evaluation of anti-PD-(L)1 immunotherapy efficacy
- Volunteers
- 350 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter
Carboplatin and Gemcitabine Hydrochloride With or Without Vandetanib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Urinary Tract Cancer
RATIONALE: Drugs used in chemotherapy, such as carboplatin and gemcitabine hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter, Ureter Cancer, Urethral Cancer
- Trial name
- NCT01191892
- Testing
- carboplatin, gemcitabine hydrochloride, vandetanib
- Where
- 21 sites in United Kingdom
- Volunteers
- 82 people
- Sponsor
- Cardiff University
Decision Making, Shared, Stereotactic Body Radiation Therapy
Shared Decision Making on Radiation Dose for Lung Malignancies
A Patient Decision Aid (PtDA) is developed during a workshop in close collaboration with selected patients. The PtDA is subsequently used in the consultation between patient and physician to facilitate their shared decision on…
- Conditions
- Decision Making, Shared, Stereotactic Body Radiation Therapy, Lung Cancer, Non-small Cell, Radiation Toxicity
- Trial name
- NCT04940936
- Testing
- A Patient Decision Aid
- Where
- Denmark
- Volunteers
- 40 people
- Sponsor
- Vejle Hospital
Lung Cancer
Radiation Therapy in Preventing Brain Metastases in Patients With Small Cell Lung Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. It is not yet known which regimen of radiation therapy may be more effective in preventing brain metastases.
- Trial name
- NCT00006344
- Testing
- radiation therapy
- Where
- United States
- Sponsor
- Virginia Commonwealth University
Carcinoma, Non-Small-Cell Lung
Afatinib Osimertinib Sequencing NIS
This is a non-interventional, multi-country, multi-centre cohort study based on existing data from medical records of patients with EGFR mutation-positive advanced NSCLC treated with afatinib (Gi(l)otrif®) as the first-line…
- Trial name
- NCT03370770
- Testing
- Afatinib, Osimertinib
- Where
- Austria
- Volunteers
- 204 people
- Sponsor
- Boehringer Ingelheim
Metastatic Colon Adenocarcinoma, Metastatic Colorectal Carcinoma
LY3214996 and Cetuximab Alone or in Combination With Abemaciclib for the Treatment of Unresectable or Metastatic Colorectal Cancer
This phase Ib/II trial investigates the side effects and best dose of LY3214996 when given together with cetuximab alone or in combination with abemaciclib and to see how well they work in treating patients with colorectal cancer…
- Conditions
- Metastatic Colon Adenocarcinoma, Metastatic Colorectal Carcinoma, Metastatic Rectal Adenocarcinoma, Recurrent Colorectal Carcinoma
- Trial name
- NCT04616183
- Testing
- Abemaciclib, Cetuximab, ERK1/2 Inhibitor LY3214996
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- M.D. Anderson Cancer Center
Upper Tract Urothelial Carcinoma
Feasibility of Neo-adjuvant Versus Adjuvant Chemotherapy in Upper Tract Urothelial Carcinoma
The aim of this study is to explore feasibility of Upper Tract Urothelial Carcinoma (UTUC) treatments based in real world data in various European countries.
- Trial name
- URANUS (NCT02969083)
- Testing
- RNU, Gemcitabine/Cisplatin, M-VAC Protocol
- Where
- 29 sites in Netherlands, Norway and 1 more
- Volunteers
- 200 people
- Sponsor
- The European Uro-Oncology Group
Lung Cancer (Non-Small Cell)
A Phase II Study of SKB571 in Patients With Lung Cancer
This is a multicenter, phase II study. The purpose of this study is to evaluate the safety and preliminary anti-tumor activity of SKB571 in patients with advanced non-small cell lung cancer.
- Trial name
- NCT07230405
- Testing
- SKB571 for injection
- Where
- 2 sites in China
- Volunteers
- 295 people
- Sponsor
- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Lung Cancer - Non Small Cell
RaFIST: A Radiomics-Based Tool for Intratumoral Fibrosis Stratification in Non-Small Cell Lung Cancer
Patients with suspected Lung cancer who underwent contrast-enhanced CT and pathological examinations at Center 1 between January 2011 and January 2020 and Center 2 between September 2017 and Januray 2020 were eligible for…
- Trial name
- NCT06908005
- Testing
- CT radiomic analysis, Fibrosis assessment
- Where
- China
- Volunteers
- 508 people
- Sponsor
- Jinling Hospital, China
Extensive Stage Small Cell Lung Cancer, Recurrent Small Cell Lung Cancer
7-hydroxystaurosporine and Topotecan Hydrochloride in Treating Patients With Relapsed or Progressed Small Cell Lung Cancer
This phase II trial is studying how well giving UCN-01 together with topotecan works in treating patients with small cell lung cancer that relapsed or progressed after previous chemotherapy.
- Trial name
- NCT00098956
- Testing
- topotecan hydrochloride, 7-hydroxystaurosporine
- Where
- Canada
- Volunteers
- 19 people
- Sponsor
- National Cancer Institute (NCI)
Small Cell Lung Cancer
Carboplatin and Etoposide Plus LBH589 for Small Cell Lung Cancer
The subjects are being asked to take part in the Phase I or Phase II portion of a research study of a new investigational drug, LBH589, in combination with chemotherapeutic agents, carboplatin with etoposide.
- Trial name
- NCT00958022
- Testing
- LBH589 and carboplatin with etoposide
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Ahmad Tarhini
Endometriosis, Deep Endometriosis
The Association Between Deep Endometriosis and the Occurrence of Colorectal Carcinoma
The goal of this study is to identify the molecular or genetic mechanisms that may predispose patients with bowel endometriosis to an increased risk of colorectal carcinoma.
- Conditions
- Endometriosis, Deep Endometriosis, Bowel Endometriosis, Colorectal Carcinoma
- Trial name
- NCT07386431
- Volunteers
- 30 people
- Sponsor
- University Medical Centre Ljubljana
Metastatic Cancer, Soft Tissue Sarcoma
A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in Metastatic or Advanced Solid Tumors
This is a Phase I/IIa, multicenter, open-label, consecutive cohorts, dose-escalation study of BT-001 with repeated IT administrations alone and in combination with IV infusions of pembrolizumab.
- Conditions
- Metastatic Cancer, Soft Tissue Sarcoma, Merkel Cell Carcinoma, Melanoma
- Trial name
- NCT04725331
- Testing
- BT-001, Pembrolizumab [KEYTRUDA®]
- Where
- 5 sites in Belgium, France
- Volunteers
- 31 people
- Sponsor
- Transgene
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.